



Corres. and Mail  
**BOX AF**

**RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE REQUESTED  
EXAMINING GROUP 1632  
PATENT  
Customer No. 22,852  
Attorney Docket No. 07680.0019**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Application of:**

David MEEKER et al.

Application No.: 09/884,526

Filed: June 19, 2001

For: COMBINATION ENZYME  
REPLACEMENT, GENE THERAPY  
AND SMALL MOLECULE THERAPY  
FOR LYSOSOMAL STORAGE  
DISEASES

## Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

**TRANSMITTAL LETTER**

Enclosed is a reply to the Final Office Action of February 18, 2004.

The claims are calculated below:

	Claims Remaining After Amendment		Highest Number Previously Paid	Present Extra	Rate	Additional Fee
Total	7	-	11	0	x \$ 18	\$ 0
Indep.	1	-	1	0	x \$ 86	0
<input type="checkbox"/> First Presentation of Multiple Dep. Claim(s)					+\$290	
					Subtotal	\$
					Reduction by ½ if small entity	-
					TOTAL	\$ 0

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Dated: May 17, 2004

By: E Stewart Mittler  
E. Stewart Mittler  
Reg. No. 50.316

**RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE REQUESTED  
EXAMINING GROUP 1632  
PATENT  
Customer No. 22,852  
Attorney Docket No. 07680.0019-00000**



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
David MEEKER et al. ) Group Art Unit: 1632  
Application No.: 09/884,526 ) Examiner: S. Chen  
Filed: June 19, 2001 )  
For: COMBINATION ENZYME )  
REPLACEMENT, GENE ) MAIL STOP: AF  
THERAPY AND SMALL )  
MOLECULE THERAPY FOR )  
LYSOSOMAL STORAGE )  
DISEASES )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RESPONSE AFTER FINAL UNDER 37 C.F.R. § 1.116**

This paper is filed in reply to the Final Office Action dated February 18, 2004.

Applicants respectfully request reconsideration of this application in view of the following amendments and remarks.

**Amendments to the claims** are reflected in the list of claims which begins on page 2 of this paper.

**Remarks** begin on page 4 of this paper.